<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806830</url>
  </required_header>
  <id_info>
    <org_study_id>EVAGO</org_study_id>
    <nct_id>NCT02806830</nct_id>
  </id_info>
  <brief_title>Ocular Discomfort Assessment After Intravitreal Injections</brief_title>
  <acronym>EVAGO</acronym>
  <official_title>Evaluation de la gêne Oculaire après Injections intravitréennes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, ocular discomfort following intravitreal injection in naïve patients will be
      studied, as well as the efficacy of wetting agent (Optive eyewash) to prevent ocular
      discomfort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In naive patients, the two first intravitreal injections will be studied. Within the first
      injection, no wetting agent will be delivered. Within 72hours after this first intravitreal
      injections, patients will be contacted by phone by a nurse to complete questionnaires on
      quality of life and on ocular pain and eye discomfort.

      After the second injection, a treatment with wetting agent will be prescribed. With 72hours
      after the second injection, quality of life, ocular discomfort as well as acceptability and
      tolerance of the eye drops will also be assessed by a phone questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the overall scores of the ocular discomfort questionnaire after the 2 first intravitreal injection in naïve patients</measure>
    <time_frame>within the 72h after the first and the second intravitreal injections</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Retinal Artery Occlusion</condition>
  <condition>Myopia, Degenerative</condition>
  <arm_group>
    <arm_group_label>Optive after the second anti-VEGF injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optive</intervention_name>
    <description>Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days</description>
    <arm_group_label>Optive after the second anti-VEGF injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Patient with social healthcare

          -  Patient understanding French language

          -  Patient requiring anti-VEGF treatment by intravitreal injection

        Exclusion Criteria:

          -  Patient treated by Ozurdex® before

          -  Patient with known and treated ocular dryness

          -  Non naive patient for intravitreal injection

          -  Hypersensitivity to Carmellose

          -  Patient who received wetting agent within the 3 last months

          -  History of povidone-iodine allergy

          -  Pregnant or breastfeeding mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oudy SEMOUN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Créteil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chi Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ba J, Peng RS, Xu D, Li YH, Shi H, Wang Q, Yu J. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Devel Ther. 2015 Sep 28;9:5397-405. doi: 10.2147/DDDT.S86269. eCollection 2015. Review.</citation>
    <PMID>26451092</PMID>
  </reference>
  <reference>
    <citation>Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998 Mar;105(3):412-6.</citation>
    <PMID>9499769</PMID>
  </reference>
  <reference>
    <citation>Nghiem-Buffet S, Cohen SY. [Retinal vein occlusion: anti-VEGF treatments]. J Fr Ophtalmol. 2009 Nov;32(9):679-86. doi: 10.1016/j.jfo.2009.10.002. Epub 2009 Oct 29. Review. French.</citation>
    <PMID>19879018</PMID>
  </reference>
  <reference>
    <citation>Salam A, DaCosta J, Sivaprasad S. Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol. 2010 Jul;94(7):821-6. doi: 10.1136/bjo.2009.163576. Epub 2009 Jun 24. Review.</citation>
    <PMID>19556214</PMID>
  </reference>
  <reference>
    <citation>Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010 Nov;33(11):2399-405. doi: 10.2337/dc10-0493.</citation>
    <PMID>20980427</PMID>
  </reference>
  <reference>
    <citation>Stewart MW. The clinical utility of aflibercept for diabetic macular edema. Diabetes Metab Syndr Obes. 2015 Sep 18;8:473-82. doi: 10.2147/DMSO.S72792. eCollection 2015. Review.</citation>
    <PMID>26425104</PMID>
  </reference>
  <reference>
    <citation>Massamba N, Elluard M, Agoune W, Guyader V, Ingram A, Pasquier B, Knoeri J. Assessment of ocular pain following ranibizumab intravitreal injection. Acta Ophthalmol. 2015 May;93(3):e231-2. doi: 10.1111/aos.12531. Epub 2014 Aug 13.</citation>
    <PMID>25123226</PMID>
  </reference>
  <reference>
    <citation>Meyer CH, Krohne TU, Charbel Issa P, Liu Z, Holz FG. Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections. Dev Ophthalmol. 2016;55:63-70. doi: 10.1159/000431143. Epub 2015 Oct 26. Review.</citation>
    <PMID>26501462</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Oudy SEMOUN</investigator_full_name>
    <investigator_title>Doctor in ophtalmology</investigator_title>
  </responsible_party>
  <keyword>Intravitreal injection</keyword>
  <keyword>AMD</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>Retinal Artery Occlusion</keyword>
  <keyword>Myopia, Degenerative</keyword>
  <keyword>eye drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Retinal Artery Occlusion</mesh_term>
    <mesh_term>Myopia, Degenerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

